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Clathrin-coated vesicles (CCVs) mediate transport
between the plasma membrane, endosomes and the
trans Golgi network. Using comparative proteomics, we
have identified coated-vesicle-associated kinase of 104
kDa (CVAK104) as a candidate accessory protein for CCV-
mediated trafficking. Here, we demonstrate that the
protein colocalizes with clathrin and adaptor protein-1
(AP-1), and that it is associated with a transferrin-positive
endosomal compartment. Consistent with these observa-
tions, clathrin as well as the cargo adaptors AP-1 and
epsinR can be coimmunoprecipitated with CVAK104.
Small interfering RNA (siRNA) knockdown of CVAK104 in
HeLa cells results in selective loss of the SNARE proteins
syntaxin 8 and vti1b from CCVs. Morpholino-mediated
knockdown of CVAK104 in Xenopus tropicalis causes
severe developmental defects, including a bent body axis
and ventral oedema. Thus, CVAK104 is an evolutionarily
conserved protein involved in SNARE sorting that is
essential for normal embryonic development.
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Clathrin-coatedvesicles(CCVs)areimportanttransportinter-
mediates that facilitate the movement of cargo proteins
between the plasma membrane, the endosomal system
and the trans Golgi network (TGN) (1). The outer shell of the
CCV consists of a clathrin lattice, attached to the membrane
by interactions with various adaptor proteins (APs), which
are also responsible for the sorting of integral membrane
cargo proteins into the CCV (2). There are two structurally
similarAPcomplexesassociatedwithCCVs,AP-1andAP-2,
both of which sort a broad range of cargo molecules.
Although AP-1 and AP-2 perform analogous functions, they
are confined to different CCV pathways. While AP-2 is the
principle adaptor for clathrin-mediated endocytosis, AP-1 is
involved in intracellular trafficking between the TGN and
endosomes. The directionality of the AP-1 pathway, i.e.,
whether it is TGN-to-endosome, endosome-to-TGN or
both, is still unclear (1,3–5).
In addition to the AP complexes, there is a growing number
ofso-called‘alternativeadaptors’,whichmediatethesorting
of specific cargo molecules. An example is the intracellular
adaptor epsinR, which sorts the SNARE vti1b (6). There are
also numerous regulatory proteins required for the forma-
tion, fission, uncoating, movement and targeting of CCVs
(3). The importance of these ‘accessory proteins’ has been
increasingly recognized over the past few years, andseveral
proteomicinvestigationshavebeencarriedouttodetermine
the complement of proteins present in CCVs (7–9). One of
the novel proteins that was thus discovered is coated-
vesicle-associated kinase of 104 kDa [CVAK104 (10)], a pro-
tein with a predicted kinase fold that was found to copurify
with CCVs from rat brain (7) and HeLa cells (9), as well as
with AP preparations from bovine brain (10). CVAK104 is
highly conserved among eukaryotes, suggesting that it may
be an important regulator of CCV-mediated protein traffick-
ing. A biochemical characterization of CVAK104 showed
that it is able to bind to clathrin and to AP-2, and to phos-
phorylate the b subunit of AP-2 in vitro, implying a role in
clathrin-mediated endocytosis (10).
In this study, we investigate the function of CVAK104
using a combination of cell and developmental biology. We
present evidence that in spite of its ability to interact with
AP-2 in vitro, CVAK104 is involved in non-endocytic,
intracellular CCV trafficking. Our results complement and
extend those of an independent study on CVAK104 by
Du ¨wel and Ungewickell (11), which was published while
this manuscript was in preparation.
Results
Identification of CVAK104 in CCVs
We have recently developed a comparative proteomics
approach to identify novel components of CCVs (9). CCV-
enriched fractions are prepared from HeLa cells and ‘mock
CCV’ fractions from cells that were depleted of clathrin by
small interfering RNA (siRNA) knockdown. Comparison of
control and mock CCV fractions allows the identification of
bona fide CCV proteins as those depleted or absent from
the mock CCV fraction. To facilitate the comparison of
mock and control CCVs, we have used (among other
techniques) fluorescent two-dimensional difference gel
electrophoresis (2D-DIGE). Fractions were labelled with
www.traffic.dk 893two different fluorescent dyes, pooled and analysed in
single 2D gels (Figure 1A). This technique allows us to
distinguish proteins that are present in similar quantities in
both fractions (red þ green ¼ yellow spots), and thus
contaminants, from proteins that are depleted or absent
from the mock CCVs (red spots) and thus candidate CCV
proteins. Using this approach in conjunction with mass
spectrometry (MS), we were able to identify both known
and unknown CCV components (9). One of the most
promising (and at the time uncharacterized) of these
proteins was the kinase-like CVAK104, which appears as
a series of red spots in Figure 1A.
A diagram of the domain organization of CVAK104 is
shown in Figure 1B. CVAK104 is related to a yeast protein,
Scy1p, and the homology between the two proteins
extends well beyond the N-terminal kinase-like domain.
Interestingly, all of the members of the Scy1 family have
kinase-like domains that lack key residues for enzymatic
activity. The clathrin- and AP-2-binding domain on
CVAK104 was mapped by Du ¨wel and Ungewickell (11) to
residues 699–929 at the C-terminus of the molecule.
Secondary structure predictions indicate that the portion
of the protein between the kinase-like domain and the
clathrin-binding domain has a high a-helical content, while
Figure 1: Identification and characterization of CVAK104. A) 2D-DIGE analysis of CCVs. The CCV-enriched fractions were prepared
from untreated HeLa cells, and ‘mock’ CCV fractions from clathrin-depleted HeLa cells. Fractions were labelled with fluorescent dyes and
analysed in single 2D gels. The figure shows a false-colour overlay of control CCV (red) and mock CCV (green) fractions. Red spots
correspond to proteins that are depleted from the mock CCVs, and thus to candidate CCV components. Yellow spots correspond to
contaminants, which are similarly abundant in both fractions. Arrowheads indicate proteins that were identified by MS. B) Schematic
diagram of CVAK104 organization, showing the positions of the kinase-like domain and the clathrin-binding domain [mapped by Du ¨wel and
Ungewickell (11)]. Homology between the CVAK104 and the Saccharomyces cerevisiae protein Scy1p was determined by BLAST (http://
www.ncbi.nlm.nih.gov/BLAST/). The predicted secondary structure downstream from the kinase-like domain was determined by JPRED
(http://www.compbio.dundee.ac.uk/). C) Western blots of cell homogenates ( 7.5 mg protein/lane) and CCV fractions ( 2 mg protein/lane)
were probedwith a new polyclonalantibody againstCVAK104. The antibodylabels an  104-kDa band,which disappears whenCVAK104is
knocked down with siRNA. The protein is highly enriched in CCVs, and undetectable in mock CCVs. This particular enrichment/depletion
profile is characteristic of proteins involved in intracellular clathrin-mediated transport (9). D) HeLa cells were extracted with 0.5% IGEPAL
and immunoprecipitated with antibodies against CVAK104, AP-2 a and AP-1 g in conjunction with protein A, or with protein A beads only
(control). Proteins identified by MS are indicated with numbers. The identification of AP-1 and AP-2 subunits other than those directly
recognized by the antibodies shows that the experimental conditions were appropriate to co-immunoprecipitate stable protein complexes.
CHC, clathrin heavy chain; kd, knockdown; TfR, transferrin receptor; EF, ribosomal elongation factor.
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type of structure, consisting of one or more folded
domains, followed by a disordered segment containing
motifs that bind to clathrin and/or adaptors, is found in
many of the components of CCVs, including AP com-
plexes, alternative adaptors and accessory proteins (2).
To characterize CVAK104, we raised a polyclonal antibody
against its disordered C-terminal domain. This antibody
recognizes a band of  104 kDa on Western blots of HeLa
cell homogenates, which disappears almost completely
when CVAK104 is knocked down with siRNA (Figure 1C).
The Western blot confirms that CVAK104 is highly enriched
in control CCV preparations (the homogenate lanes contain
four times as much protein as the CCV lanes), and it is
almost completely undetectable in mock CCVs, indicating
that it is a bonafidecomponent of CCVs. Wehavepreviously
shown that AP-1 and AP-2 have different enrichment and
depletion profiles under these conditions, with AP-1 show-
ing much greater enrichment in CCVs and greater depletion
from mock CCVs than AP-2 (9). Based on these criteria, the
enrichment and depletion profile of CVAK104 is indicative of
an association with AP-1 positive, non-endocytic CCVs.
To identify putative interaction partners of CVAK104, the
antibody was used to immunoprecipitate detergent
(IGEPAL) extracts of HeLa cells (Figure 1D). A single
precipitated band was detectable on Coomassie blue-
stained gels, which was shown by MS to correspond to
CVAK104. No obvious candidate binding partners were
observed, suggesting that CVAK104’s interactions with
other proteins are transient or weak.
Localization, dynamics and membrane association
of CVAK104
To determine the localization of CVAK104, we used the
antibody for immunofluorescence microscopy, mixing
together control and CVAK104-depleted cells (Figure 2A).
CVAK104 is localized to the perinuclear region of the cell as
well as to more peripheral structures, and this pattern
disappears when CVAK104 is knocked down using siRNA,
confirming the specificity of the labelling. Double labelling
for other coat proteins shows extensive (although not
complete) colocalization between CVAK104 and clathrin
(Figure 2B), and between CVAK104 and AP-1 (Figure 2C).
However, CVAK104 shows no apparent colocalization with
AP-2(Figure 2D),eventhough it canbindtoAP-2invitro(10).
To further characterize the nature of CVAK104’s associa-
tion with membranes, we used the drug brefeldin A (BFA),
which prevents the small guanosine triphosphatase ADP
ribosylation factor (ARF) from binding to membranes. The
BFA causes AP-1 and other intracellular coat components
to redistribute to the cytosol, but it does not affect the
association of AP-2 with the plasma membrane (12). The
HeLa cells were treated with BFA for 5 minutes, then
imaged by immunofluorescence microscopy (Figure 2E).
Upon treatment with BFA, CVAK104 became largely
cytosolic, indicating that its association with membranes
is mediated by ARF. Collectively, these findings suggest
that CVAK104 is associated with intracellular rather than
endocytic CCVs.
To observe the dynamics of CVAK104 in living cells, we
transiently transfected HeLa cells with a CVAK104-green
fluorescent protein (GFP) fusion protein. Like native
CVAK104, CVAK104-GFP localizes to intracellular vesicular
structures with no significant labelling of the plasma
membrane (Figure 3A). The video link (Video S1) shows
that many of these structures are highly mobile. To ensure
that GFP tagging does not alter the targeting of CVAK104,
we also imaged CVAK-GFP by immunofluorescence
microscopy in fixed HeLa cells. The fusion protein has
a very similar distribution to endogenous CVAK104 and
colocalizes substantially with AP-1 (Figure S1A). This
suggests that the observed live-cell movements of
CVAK-GFP are likely to reflect those of untagged
CVAK104. To determine how clathrin affects the targeting
of CVAK104, we transiently expressed CVAK104-GFP in
HeLa cells that had been depleted of clathrin heavy chain
by siRNA knockdown (Figure 3B and Video S2). In general,
the distribution of CVAK104-GFP appeared to be more
cytosolic in clathrin-depleted cells; however, a significant
pool of CVAK104-GFP remained associated with vesicular
structures, which were largely immobile. In addition, we
observed an association of CVAK104-GFP with mobile
tubular structures (white arrows in Figure 3B), indicating
that CVAK104 is capable of binding to membranes in
a clathrin-independent manner.
The binding site on CVAK104 for clathrin is located in its
C-terminal disordered region (11). Because the N-terminal
domain of CVAK104 has a predicted kinase fold, we
speculated that this part of the protein may also be
a functionally important unit. To assess whether the
kinase-like domain carries any targeting information, we
attached yellow fluorescent protein (YFP) to a truncated
version of CVAK104 (residues 1–387) and transiently ex-
pressed it in HeLa cells (Figure 3C and Video S3). This
construct too was able to localize to membranes, associ-
ating bothwith mobile vesicular structures andwith mobile
tubules. The vesicular but not the tubular structures
showed substantial colocalisation with endogenous
CVAK104 and AP-1, as ascertained by immunofluores-
cence of fixed HeLa cells (Figure S1B). Expression of the
truncated YFP construct in HeLa cells that had been
depleted of clathrin heavy chain showed increased label-
ling of the mobile tubular structures (Figure 3D and Video
S4). Together, our findings demonstrate that the kinase-
like domain of CVAK104 contains targeting information
that allows binding to an intracellular compartment, inde-
pendently of clathrin.
To determine the identity of the CVAK104-positive mem-
branes, we monitored the uptake of transferrin in HeLa
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S5,S6). Fluorescently labelled transferrin was pre-bound
at 4 8C, and then the cells were warmed to 37 8C and
imagedimmediately.Therewassubstantialcolocalizationbe-
tween CVAK104-GFP and transferrin at early time-points
(Figure 3E, 1 and 10 minutes; Video S5) but not at later
time-points (Figure 3E, 60 minutes; Video S6), indicating
that like AP-1, CVAK104 is at least partially associated with
early and/or recycling endosomes.
Functional characterization of CVAK104 in HeLa cells
To investigate the function of CVAK104, we used siRNA to
deplete the protein in HeLa cells and then examined the
phenotype. In most respects, the cells appeared to be
normal. CVAK104 depletion had no apparent effect on the
localization of either AP-1 or AP-2, or on the steady-state
distribution or surface expression of the chimeric proteins
CD8-furin and CD8-CIM6PR (unpublished data), both of
which are highly sensitive to disturbances in AP-1-medi-
ated trafficking (13). Transferrin recycling, which is also
affected by AP-1 knockdown (13), was similarly unaltered
by CVAK104 depletion (unpublished data). We also inves-
tigated whether CVAK104 influences the protein compo-
sition of CCVs by preparing CCV-enriched fractions from
control cells and from cells that had been depleted of
CVAK104 by siRNA knockdown and then analysing the
two fractions by 2D-DIGE. The only protein that changed
substantially was CVAK104 itself (unpublished data), indi-
cating that the absence of CVAK104 does not result in any
major changes in CCV composition.
Figure 2: Immunolocalization of CVAK104.
A) HeLa cells were either treated with siRNA
against CVAK104 or untreated (control), then
mixed and labelled with anti-CVAK104 anti-
body. Asterisks indicate CVAK104-depleted
cells. Scale bar: 10 mm. B–D) Double labelling
for CVAK104 and coat proteins. B) HeLa cells
were double labelled for CVAK104 and CHC.
The two patterns show significant colocaliza-
tion. C) HeLa cells were double labelled for
CVAK104 and AP-1 g. Again the two patterns
show significant colocalization. D) HeLa cells
were double labelled for CVAK104 and AP-2
a. The two patterns show no significant
colocalization. Scale bars: 5 mm. E) HeLa cells
were treated with BFA (20 mg/mL) for 5
minutes at 37 8C or treated with medium only
(control), and labelled with anti-CVAK104 anti-
body. Upon BFA treatment, CVAK104 loses its
membrane association and becomes largely
cytosolic. Scale bars: 10 mm. CHC, clathrin
heavy chain. Arrowheads indicate areas of
colocalisation.
896 Traffic 2007; 8: 893–903
Borner et al.Next, we considered the possibility that CVAK104 might
contribute to the sorting of a subset of CCV cargo mole-
cules. In our previous proteomic analysis of CCVs, we
established that at least 10 TGN and endosomal SNARES
are associated with CCVs (9). This strongly suggests that
many post-Golgi SNARES are trafficked in a clathrin-depen-
dent manner; however, it is not generally known how they
are selectively incorporated into CCVs (14).
To investigate a potential function for CVAK104 in post-
Golgi SNARE trafficking, CCVs (or mock CCVs) were
prepared from control, clathrin-depleted and CVAK104-
depleted cells. Western blots of the fractions were then
probed for 10 different SNAREs, including syntaxin 6, 7, 8
and16; vti1a andvti1b; VAMP 3,4 and 7 andSNAP29, all of
which are constituents of CCVs (9). While the majority of
SNAREs were unaffected or only marginally affected by
CVAK104 depletion, there was a significant and highly
reproducible loss of syntaxin 8 and vti1b (Figure 4 and
unpublished data), indicating that CVAK104 helps to pack-
age these SNAREs into CCVs. We suspect that syntaxin 8
and vti1b are sorted as a dimer because they are known to
interact with each other and to depend on each other for
stability, to the extent that vti1b knockout mice also lose
syntaxin 8 (15).
Vti1b requires both AP-1 and epsinR for correct packaging
into CCVs; in fact, the observed loss of vti1b from CCVs in
Figure 3: Live-cell imaging of tagged
CVAK104 constructs. A and B) CVAK104
was tagged with GFP at the C-terminus
and transiently expressed in HeLa cells. A)
In control cells, CVAK104-GFP is present in
small and highly mobile compartments. B)
In clathrin-depleted cells, CVAK104-GFP is
more cytosolic but also labels largely
immobile vesicular compartments as well
as mobile tubular structures (white ar-
rows). C and D) The N-terminal kinase-like
domain of CVAK104 was tagged with YFP
and transiently expressed in HeLa cells. C)
In control cells, the construct localizes to
mobile tubular and vesicular structures. D)
In clathrin-depleted cells, the construct
localizes mainly to tubular mobile struc-
tures. E) CVAK104-GFP was transiently
expressed in HeLa cells. Cells were al-
lowed to endocytose pre-bound Alexa
Fluor-labelled transferrin, and imaged
either  1,  10 or  60 minutes after begin-
ning of uptake by spinning-disk confocal
microscopy. Frequent colocalization (white
arrows) can be observed at early, but not at
late stages of the experiment. Time-points
1 and 10 minutes show images of the
same cell, taken from a continuous movie
(Video S5). Representative still images are
shown here; the corresponding movies are
available as Videos S1–S6 (online supple-
mental material). Scale bars: 10 mm.
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for AP-1 or epsinR knockdowns (6). We therefore investi-
gated a possible link between CVAK104 and AP-1/epsinR.
Because our initial biochemical characterization indicated
that CVAK104’s interactions with other proteins are labile
(Figure 1D), we performed CVAK104 immunoprecipita-
tions from digitonin extracts of HeLa cells. These gentle
conditions leave many of the more delicate cargo protein
interactions intact (unpublished observation). Analysis by
Western blot revealed that CVAK104 co-immunoprecipi-
tates clathrin, AP-1 g and epsinR (Figure 5), suggesting
that CVAK104 may directly regulate the function of these
proteins. Under the same conditions, no co-immunopre-
cipitation of the cation-independent mannose 6-phosphate
receptor (CIMPR) or the AP-3 m subunit was observed.
CVAK104 and Xenopus development
Mice with a deletion in the vti1b gene and concomitant
destabilization of syntaxin 8 have been reported to be
viable and healthy (15). Thus, if the only function of
CVAK104 is to assist the sorting of syntaxin 8 and vti1b,
CVAK104 depletion in an animal should also produce a very
mild phenotype. To test this hypothesis, one-celled Xeno-
pus tropicalis embryos were injected with a morpholino
(MO) antisense oligonucleotide to knockdown CVAK104.
Figure 6A (panels 1, 2, 5 and 6) shows that the phenotype
of CVAK104-depleted embryos is in fact severe. Abnor-
malities include reduced axial extension, bent anterior–
posterior axis and ventral oedema.
To ensure that the CVAK104 knockdown phenotype was
specifically caused by the depletion of the protein and not
by off-target effects, we carried out a ‘rescue’ experiment,
in which we co-injected the embryos with the MO as well
as with messenger RNA (mRNA) encoding myc-tagged
human CVAK104. The human and frog proteins are 77%
identical and because of sequence variation at the mRNA
level, human CVAK104 is not targeted by the MO. The
tagged protein was detectable by Western blotting in both
control and MO-treated embryos (Figure 6B). Expressing
human CVAK104 in control embryos had no apparent
effect (Figure 6A, panels 4 and 8), indicating that elevated
levels of the protein are not toxic. The embryos that were
co-injected with human CVAK104 mRNA and MO showed
a high level of rescue at both tailbud and tadpole stages
(Figure 6A, panels 3 and 7), indicating that the effects of
MO knockdown are indeed specific to depletion of
CVAK104.
To obtain reference phenotypes for defects in clathrin-
mediated trafficking, we also performed MO knockdowns
of AP-1 (m1A) and AP-2 (m2) (Figure 6C). The AP-2-
depleted embryos arrested very early during development,
and none survived beyond the tailbud stage. In contrast,
AP-1 knockdown resulted in a phenotype that shares some
similarities with that of CVAK104 knockdown, including
a shortened and bent anterior–posterior axis and ventral
oedema. Together, these observations indicate that, like
AP-1 and AP-2, CVAK104 is needed for normal embryonic
development, suggesting that it has other functions in
addition to its role in sorting syntaxin 8 and vti1b.
Figure 4: CVAK104 kd results in specific depletion of syntax-
in 8 and vti1b from CCVs. Cell homogenates and CCV fractions
were prepared from control and siRNA-treated cells and analysed
by Western blot. CVAK kd1 and CVAK kd2 denote samples from
two independent kd experiments. Approximately 10 mg protein of
whole cell lysates or 2.5 mg of CCV fractions were loaded in each
lane. Although the four SNAREs, syntaxin 7, syntaxin 8, vti1a, and
vti1b, are all sorted by clathrin, only syntaxin 8 and vti1b are
depleted from CCVs in a CVAK104 kd. CHC, clathrin heavy chain;
kd, knockdown.
Figure 5: CVAK104 interacts with clathrin, AP-1 and epsinR.
HeLa cells were extracted with 1% digitonin and immunoprecipi-
tated with an antibody against CVAK104 in conjunction with
protein A linked to Sepharose beads, or with protein A beads only
(control). Immunoprecipitates were analysed by Western blot.
CHC, clathrin heavy chain.
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In this study, we have identified and characterized
CVAK104 as a novel accessory protein for intracellular
CCV-mediated trafficking. Our findings are in good agree-
ment with those of an independent study by Du ¨wel and
Ungewickell (11), and they significantly advance our under-
standing ofCVAK104functionbydemonstratingitsinvolve-
ment in SNARE sorting and in embryonic development.
CVAK104 is unlikely to be involved in endocytosis
Conner and Schmid (10) and Du ¨wel and Ungewickell (11)
showed that CVAK104 can bind to AP-2 in vitro, suggest-
ing that it functions in clathrin-mediated endocytosis.
Figure 6: CVAK104knockdown and rescue in Xenopus. A) Fertilized X. tropicalis eggs were injected with a control MO (panels 1 and 5)
or a MO against CVAK104 (panels 2 and 6) at the one-cell stage and imaged either 24 h or 48 h post-fertilization. To rescue the knockdown
phenotype, fertilized eggs were injected with anti-CVAK104 MO þ mRNA encoding human CVAK104-myc (panels 3 and 7), then imaged
either24h or 48hpost-fertilization. Expressionof humanCVAK104-mycresultedinhigh levelsof rescuebothattailbudandtadpolestages.
Expression of human CVAK104-myc alone had no apparent detrimental effects (panels 4 and 8). B) Western blots of extracts from 24 h
embryos were probed with anti-myc antibody. AP-2 m2 was included as a loading control. Human CVAK104-myc was detectable in embryos
that had been injected with mRNA. C) Fertilized eggs were injected with either a control MO, a MO against AP-2 m2, or a MO against AP-1
m1A, then imaged either 24 h or 48 h post-fertilization. Both knockdowns cause severe phenotypes, but the AP-1 knockdown phenotype is
more similar to the CVAK104 knockdown phenotype.
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the plasma membrane and instead indicate that it func-
tions in intracellular trafficking. First, by Western blotting,
CVAK104 shows enrichment in CCVs and depletion from
mock CCVs similar to that of AP-1, not AP-2 (Figure 1C) (9).
Second, CVAK104 colocalizes with AP-1 but not with AP-2
(Figure 2). Third, endocytosed transferrin colocalizes with
CVAK104-GFP in an early endosomal compartment but not
at the plasma membrane (Figure 3E). Similar colocalization
data were reported by Du ¨wel and Ungewickell (11).
Fourth, CVAK104 is important for the sorting of syntaxin
8 and vti1b, which reside in intracellular membranes
(Figure 4). Fifth, AP-1 and epsinR can be coimmunopreci-
pitated with CVAK104 (Figure 5). Sixth, knockdown of
CVAK104 in Xenopus embryos results in defects that are
similar to those caused by knockdown of AP-1 but are
dissimilar to those caused by knockdown of AP-2 (Fig-
ure 6). It is also worth noting that the yeast homologue of
CVAK104, Scy1p, colocalizes with clathrin on intracellular
membranes (16).
CVAK104 targeting is only partially dependent on
clathrin
CVAK104 binds to clathrin heavy chain in vitro (10), and
Du ¨wel and Ungewickell (11) have characterized this inter-
action extensively. They showed that CVAK104’s C-termi-
nal domain (residues 699–929) mediates the interaction
with clathrin, andit is alsocapable oftargeting a GFP fusion
protein to clathrin- and AP-1-positive membranes. In
addition, they reported that CVAK104 dissociates from
membranes in clathrin-depleted cells (although by West-
ern blotting, they saw only a 30% reduction in the amount
of CVAK104 cofractionating with a membrane-containing
pellet). In contrast, we find that clathrin knockdown
reduces but does not abolish CVAK104’s membrane
association. Moreover, when we expressed a YFP fusion
of the N-terminal kinase-like domain of CVAK104, which
lacks any clathrin-binding activity (11), we found that this
construct was able to localize to intracellular membranes,
both in the presence and in the absence of clathrin
(Figures 3C,D and S1B). These membranes show partial
colocalization with internalized transferrin (unpublished
data) and are likely to correspond to the donor compart-
ment from which CVAK104-positive vesicles bud. Pre-
sumably, the C-terminal domain with the clathrin-binding
sites is neededfor CVAK104 to be packagedefficiently into
CCVs. The ability of the N-terminal domain to be targeted
to intracellular membranes on its own may also help to
explain why CVAK104 is associated with intracellular
rather than plasma membrane-derived CCVs.
CVAK104 is involved in trafficking of post-Golgi
SNAREs
The SNAREs are particularly important components of
transport vesicles because they enable the vesicles to
fuse with the appropriate acceptor compartment; how-
ever, little is known about how they are trafficked. In
a previous study, we established that numerous post-Golgi
SNAREs are present in CCVs (9). Here, we show that
knocking down CVAK104 significantly reduces the levels
of syntaxin 8 and vti1b in CCVs, indicating that CVAK104
may be part of the sorting machinery for these particular
SNAREs. Intriguingly, there was no concomitant change
in the level of syntaxin 7, even though it is part of the same
Q-SNARE complex and all three proteins are strongly
depleted from mock CCVs prepared from clathrin-depleted
cells. This has important implications for SNARE traffick-
ing. To be fusogenic, the three Q-SNAREs must form
a heterotrimer, so the observation that syntaxin 7’s
enrichment in CCVs is unaffected by CVAK104 knockdown
strongly suggests that although all three SNAREs rely on
CCVs for transport, they do not traffic as a fusion-compe-
tent complex. Whether they are sorted into different
CCVs, or are present in the same CCV but are kept apart
(e.g., by syntaxin 7 adopting its closed conformation),
remains to be determined. Either way, this presents
a possible explanation for how SNAREs can be trafficked
by CCVs without causing non-specific fusion events before
reaching their final destination.
What could be CVAK104’s mechanism of action?
CVAK104 knockdown does not lead to any global changes
in CCV composition, as judged by 2D-DIGE, and we have
not observed a direct interaction between CVAK104 and
syntaxin 8 or vti1b (unpublished data). This suggests that
CVAK104 is unlikely to function as a cargo adaptor, such as
epsinR, which binds and sorts vti1b (6). However, we have
shown that clathrin, AP-1 and epsinR can be coimmuno-
precipitated with CVAK104 (Figure 5), and all three of
these proteins are required for efficient sorting of vti1b
into CCVs (6). Because CVAK104 knockdown does not
affect the amount of epsinR (or clathrin) present in CCVs
(Figure 4), it seems likely that CVAK104 may indirectly
affect protein sorting by regulating the activity of adaptors
(e.g., epsinR, AP-1) and/or accessory proteins. Although
CVAK104 has a predicted kinase fold, it lacks key catalytic
residues, and there is some discrepancy in the literature
over whether or not CVAK104 has any enzymatic activity
(10,11). We show in the present study that this domain is
capable of targeting to intracellular membranes, and it is
possible that it may have a different function, such as to
act as a binding domain for other proteins and/or lipids.
CVAK104 knockdown has been reported to cause missort-
ing of the lysosomal enzyme cathepsin D (11), suggesting
that CVAK104 may also be required for the incorporation of
mannose 6-phosphate receptors into CCVs. In the present
study, we did not detect any effect of CVAK104 knock-
down on the distribution of the chimeric CD8-CIM6PR;
similarly, under conditions where CVAK104 clearly inter-
acts with epsinR and AP-1, we could not detect any
interaction with CIMPR (Figure 5). We did, however,
observe a very slight decrease in the levels of endogenous
CIMPR in CCVs prepared from CVAK104-depleted HeLa
cells (unpublished data). In any case, both our own findings
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in that they support a function for CVAK104 in protein
sorting at the TGN and/or endosomes.
AP-1, AP-2 and CVAK104 are important for
Xenopus development
Using X. tropicalis embryos as a model system, we have
investigated the consequences of interfering with
CVAK104 and other CCV components during develop-
ment. By knocking down CVAK104, AP-1 and AP-2, we
were able to show that all three components are required
for normal morphogenesis. Deprivation of AP-2 had the
most severe consequences; most embryos arrested at
very early stages, and none of them survived past the
tailbud stage. The AP-1 knockdown also caused serious
defects, including ventral oedema, bent anterior–posterior
axis and reduced axial extension. This highlights the
tremendous importance of clathrin-mediated trafficking
during embryogenesis, and it provides reference pheno-
types for the knockdown of other components of the CCV
machinery. Knocking down CVAK104 also caused ventral
oedema, bent anterior–posterior axis and reduced axial
extension, although not to the same extent as the AP-1
knockdown. The similarities between the two phenotypes
support the idea that AP-1 and CVAK104 function in the
same pathway. Interestingly, similar phenotypes have also
been observed in embryos injected with MOs that target
signalling molecules, such as growth factors and their
receptors (17). Our current working hypothesis is that
AP-1 and CVAK104 may help to sort these molecules,
something that can be tested by analysing CCV fractions
from control and siRNA-treated HeLa cells. Although we
have so far only examined the consequences of CVAK104
depletion in Xenopus, the evolutionary conservation of
CVAK104 between frogs and humans, as shown by the
rescue experiment, suggests that this protein plays an
important role in all vertebrates. Thus, the developing
Xenopus embryo may provide a powerful tool to investi-
gate CVAK104 function in more detail. Knockdown and
attempted rescue with deletion mutants or truncated
versions of human CVAK104 may give insights into which
domains of the protein are required for full or partial
function.
Materials and Methods
RNA interference and CCV preparations
The siRNA-mediated knockdown of clathrin heavy chain was performed
with a custom-made duplex (Dharmacon, Lafayette, CO, USA) described by
Motley et al. (18). For CVAK104 knockdowns, Dharmacon’s SMART-pool
siRNA was used (FLJ10074). Knockdowns were performed as described by
Borner et al. (9). The CCV-enriched fractions were prepared from control
and knockdown HeLa cells as described (9).
Gel electrophoresis and MS
The SDS–PAGE and Western blots were performed using standard
methods. Antibodies against the following proteins were used: AP-1 g
(mAb100/3) (Sigma-Aldrich, St Louis, MO, USA); AP-3 m3 (19); CIMPR (gift
from Paul Luzio, Cambridge Institute for Medical Research, University of
Cambridge, UK); CVAK104 (this study); clathrin heavy chain (19); c-myc (A-14)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); epsinR (20); SNAP29
(Synaptic Systems, Goettingen, Germany); AP-2 m2 (AP50), syntaxin 8,
vti1a, vti1b, (BD Transduction Laboratories, San Diego, CA, USA); syntaxin
6, syntaxin 7, syntaxin 16 (gifts from Andrew Peden, Cambridge Institute
for Medical Research, University of Cambridge, UK); VAMP 3 (Abcam,
Cambridge, UK); VAMP4 (21); VAMP7 (22). The 2D-DIGE analysis was
performed as described by Borner et al. (23). Gel pieces containing proteins
of interest were excised, and analysed by MALDI-TOF or TOF-TOF, or by
liquid chromatography (LC) tandem MS (LC-MS/MS), as described in
Borner et al. (9).
Immunoprecipitations
For immunoprecipiations, HeLa cells were extracted with 0.5% IGEPAL
CA-630 (Sigma-Aldrich) in PBS (150 mM NaCl, 25 mM phosphate buffer, pH
7.5), or with 1% digitonin (Fluka, Neu-Ulm, Germany) in 2-(N-morpholino)
ethanesulfonic acid buffer (0.1 M MES, 1 mM MgC2H5O2,0 . 5m M EGTA,
pH 6.5), supplemented with 0.2 mM protease inhibitor AEBSF (Calbiochem,
San Diego, CA, USA). Insoluble material was removed by centrifugation and
filtration (pore size of 0.2 mm). Extracts were pre-cleared by incubation with
Sepharose-coupled protein A. Antibodies were added to extracts at 1/100
dilutions (no antibody was added to control samples). Sepharose-coupled
protein A was added to recover immunoprecipiates. Sepharose beads were
washed five times in ice-cold PBS–IGEPAL (0.1%) and once in PBS, or five
times in ice-cold MES buffer (1% digitonin). Proteins were eluted with
2.5% SDS/50 mM Tris, pH 8.0 at 90 8Cf o r2  2 minutes. The following
antibodies were used: anti-CVAK104 (this study); anti-AP-2 a (24) and anti-
AP-1 g (25).
CVAK104 constructs
An expressed sequence tag encoding full-length human CVAK104 (929 aa;
IMAGE Clone ID 6473586; gi39645499) was obtained from the Sanger
Centre (UK). A rabbit polyclonal antibody was raised against a glutathione S-
transferase fusion of the C-terminal domain of CVAK104 (aa 650–920). For
live-cell imaging, DNA encoding full-length CVAK104 (aa 1–929) was
amplified by polymerase chain reaction (PCR) and cloned into the EcoR1/
BamH1 sites of pEGFP-N (Clontech, Mountain View, CA, USA). To obtain
a CVAK104-kinase domain fusion, the PCR product encoding full-length
CVAK104 was digested with EcoR1/Kpn1. The resulting fragment (base
pair 1–1161) encoded CVAK104-kinase domain (and some flanking
sequence; aa 1–387) and was cloned into the EcoR1/Kpn1 sites of
pEYFP-N (Clontech). For expression in Xenopus, a fragment encoding full-
length human CVAK104-myc (aa 1–929 þ c-myc) was amplified by PCR and
cloned into the EcoR1/Not1 sites of vector pCS107.
Immunolocalization, live-cell imaging and
transferrin uptake
For immunofluorescence microscopy, HeLa cells were either fixed with 3%
paraformaldehyde and permeabilized with 0.1% TX-100 or fixed with
methanol at  20 8C. Antibodies against the following proteins were used:
AP-1 g (mAb100/3) (Sigma-Aldrich); AP-2 a (AP.6) (a gift from Frances
Brodsky, Department of Pharmacy, School of Pharmacy, University of
California San Francisco); clathrin heavy chain (X22) (a gift from Frances
Brodsky); CVAK104 (this study); GFP (rabbit polyclonal, Abcam). For some
experiments, cells were treated with 20 mg/mL BFA for 5 minutes at 37 8C
before fixation. Cells were imaged with a Zeiss Axiovert 200 inverted
microscope using a Zeiss Plan Achromat 63  oil immersion objective, 1.40
NA, a Hamamatsu Orca ER2 camera and IMPROVISION OPENLAB software. For
live-cell work, HeLa cells were transfected with CVAK104-GFP or
CVAK104-kinase-domain-YFP for 16–18 h using FuGENE 6 (Roche Diag-
nostics, Indianapolis, IN, USA). For transferrin uptake, cells were preincu-
bated at 4 8C for 15 minutes in serum-free medium containing 1% BSA and
25 mM HEPES. Cells were then incubated at 4 8C with Alexa Fluor 594-
labelled human transferrin (Molecular Probes, Eugene, OR, USA) for 30
minutes. Cells were washed with ice-cold PBS and kept on ice until imaged.
All live-cell imaging was performed at 37 8C. Images were acquired using
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a Hamamatsu Orca ER2 camera and a Peltier-driven heated stage, using a
Zeiss Plan Achromat 63  oil immersion objective, 1.40 NA. Image se-
quences were processed using IMAGEJ (http://rsb.info.nih.gov/ij).
Morpholinos
Translation-blocking antisense morpholino oligonucleotides against AP-1
m1A, AP-2 m2 and CVAK104 were designed with the following sequences:
GCCGAAGATAGTCCTGCAAAGGCAA (AP-1 m1A) GATCTTCACTCTCTCGC
GGCTCCTC (AP-2 m2) GTTTGTTTAGCATCGACTCCATTTG (CVAK104)
The MOs were modified by addition of lissamine fluorochromes. One-
celled X. tropicalis embryos were injected with 20 ng of antisense or control
(Gene Tools standard control; Gene Tools, Philomath, OR, USA) MO in 2 nL
H2O. In rescue experiments, the 20 ng of antisense MO or control MO was
co-injected with 1.2 ng of rescue mRNA. To synthesize rescue mRNA, the
rescue construct CVAK104-myc-pCS107 was linearized by digestion with
AscI, and transcribed using the Sp6 pol mMESSAGEmMACHINE Kit
(Ambion, Austin, TX, USA) according to the manufacturer’s instructions.
Embryos were observed, photographed and fixed in 4% formaldehyde or
frozen for protein analysis at gastrula (stages 10–12), tailbud (stages 24–28)
and tadpole (stages 37–41) stages. For protein analysis, tadpoles were
homogenized in PBS-AEBSF in a Dounce homogenizer at 4 8C. Debris was
pelleted by centrifugation at 5000   g for 7 minutes. Supernatants were
analysed by Western blot.
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Supplementary Materials
Figure S1: Localisation of CVAK104-GFP and CVAK104-kinase-
domain-YFP in fixed HeLa cells. A) CVAK104-GFP was transiently ex-
pressed in HeLa cells. Cells were fixed, and AP-1 g and CVAK104-GFP were
detected by immunofluorescence microscopy. CVAK104-GFP shows a
distribution that is highly similar to endogenous CVAK104, as well as
substantial colocalisation with AP-1 g (white arrowheads). B) CVAK104-
kinase-domain-YFP was transiently expressed in HeLa cells. Cells were
fixed, and endogenous CVAK104 and CVAK104-kinase-domain-YFP were
detected by immunofluorescence microscopy. The two proteins show
substantial colocalisation in vesicular structures (white arrowheads) but not
in the kinase-domain-positive tubular structures. Note that the CVAK104
antibody was raised against the C-terminal part of the protein, and therefore
does not cross-react with the kinase-domain-YFP fusion protein. Scale bars:
5 mm.
Video S1: CVAK104-GFP expressed in HeLa cells (12 ).
Video S2: CVAK104-GFP expressed in HeLa cells depleted of clathrin
heavy chain (12 ).
Video S3: CVAK104-kinase-domain-YFP expressed in HeLa cells (12 ).
Video S4: CVAK104-kinase-domain-YFP expressed in HeLa cells depleted
of clathrin heavy chain (12 ).
Video S5: CVAK104-GFP and Alexa Fluor 594-labelled transferrin in HeLa
cells starting  1 minute after beginning of transferrin uptake (250 ).
Video S6: CVAK104-GFP and Alexa Fluor 594-labelled transferrin in HeLa
cells starting  60 minutes after beginning of transferrin uptake (250 ).
Note: Scale bars in all movies: 10 mm.
Supplemental materials are available as part of the online article at http://
www.blackwell-synergy.com
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